Please use this identifier to cite or link to this item:
|Title:||Association of polymorphisms in genes regulating the corticotropin- releasing factor system with antidepressant treatment response||Authors:||Binder, E.B.
|Issue Date:||Apr-2010||Citation:||Binder, E.B., Owens, M.J., Liu, W., Deveau, T.C., Rush, A.J., Trivedi, M.H., Fava, M., Bradley, B., Ressler, K.J., Nemeroff, C.B. (2010-04). Association of polymorphisms in genes regulating the corticotropin- releasing factor system with antidepressant treatment response. Archives of General Psychiatry 67 (4) : 369-379. ScholarBank@NUS Repository. https://doi.org/10.1001/archgenpsychiatry.2010.18||Abstract:||Context: The corticotropin-releasing factor (CRF, or corticotropin- releasing hormone) and arginine vasopressin systems have been implicated in the pathophysiology of anxiety and depressive disorders and response to antidepressant treatment. Objective: To study the association of genetic variants in 10 genes that regulate the CRF and arginine vasopressin systems with treatment response to Citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample (N= 1768). Design: Pharmacogenetic association study derived from the STAR*D study, a multieenter, prospective, open, 12-week effectiveness trial. Setting: Outpatient primary care and psychiatric clinics. Patients: Individuals with nonpsychotic major depressive disorder for whom DNA was available who were subsequently treated with Citalopram hydrobromide for 4 to 12 weeks. Intervention: Flexible doses of Citalopram. Main Outcome Measure: Association of genetic polymorphisms in genes encoding the CRF system with response and remission to Citalopram treatment at exit visit. Results: One single-nucleotide polymorphism (SNP) (rsl0473984) within the CRHBP locus showed a significant association with both remission (P=6.0 X 10 -6; corrected, P=. 0026) and reduction in depressive symptoms (P= 7.0 X 10 -7; corrected, P=.00031) in response to Citalopram. The T allele of this SNP was associated with poorer treatment outcome in 2 of the 3 ethnic subsamples (African American and Hispanic), despite large differences in minor allele frequency. This association was more pronounced in patients with features of anxious depression (P= .008). The nonresponse allele was shown to be associated with overall higher plasma corticotropin levels and more pronounced dexamethasone suppression of corticotropin. Conclusions: These data indicate that a genetic variant within the CRHBP locus affects response to Citalopram in African American and Hispanic patients, suggesting a role for this gene and for the CRF system in antidepressant treatment response. ©2010 American Medical Association. All rights reserved.||Source Title:||Archives of General Psychiatry||URI:||http://scholarbank.nus.edu.sg/handle/10635/109939||ISSN:||0003990X||DOI:||10.1001/archgenpsychiatry.2010.18|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 2, 2020
WEB OF SCIENCETM
checked on Jun 2, 2020
checked on May 30, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.